JMI Syringes & Medical Devices Limited (DSE:JMISMDL)
Bangladesh
· Delayed Price · Currency is BDT 119.10
-1.10 (-0.92%)
At close: Dec 4, 2025
DSE:JMISMDL Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| Revenue | 1,810 | 1,884 | 1,794 | 1,755 | 2,438 | 1,994 | Upgrade
|
| Revenue Growth (YoY) | -0.79% | 5.02% | 2.19% | -28.01% | 22.31% | 0.86% | Upgrade
|
| Cost of Revenue | 1,567 | 1,591 | 1,504 | 1,534 | 2,049 | 1,657 | Upgrade
|
| Gross Profit | 242.64 | 293.19 | 289.79 | 221.49 | 389.31 | 336.76 | Upgrade
|
| Selling, General & Admin | 158.15 | 156.82 | 155.77 | 141.69 | 176.37 | 150.89 | Upgrade
|
| Other Operating Expenses | 0.42 | 0.42 | 0.11 | 7.96 | - | - | Upgrade
|
| Operating Expenses | 159.17 | 157.84 | 156.49 | 150.24 | 176.97 | 151.29 | Upgrade
|
| Operating Income | 83.47 | 135.35 | 133.3 | 71.24 | 212.34 | 185.46 | Upgrade
|
| Interest Expense | -0.24 | -0.43 | -2.52 | -12.93 | -13.18 | -11.18 | Upgrade
|
| Interest & Investment Income | 1.45 | 1.45 | 0.27 | 1.42 | 6.89 | 10.4 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.5 | -7.09 | -5.31 | - | -0.18 | 0.77 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.82 | -0.17 | 5.33 | 4.73 | 1.79 | 0.71 | Upgrade
|
| EBT Excluding Unusual Items | 77.35 | 129.11 | 131.07 | 64.46 | 207.67 | 186.17 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.05 | - | Upgrade
|
| Pretax Income | 77.35 | 129.11 | 131.07 | 64.46 | 207.72 | 186.17 | Upgrade
|
| Income Tax Expense | 69.24 | 84.18 | 92.19 | 214.43 | 107.12 | 97.06 | Upgrade
|
| Net Income | 8.11 | 44.92 | 38.88 | -149.96 | 100.6 | 89.11 | Upgrade
|
| Net Income to Common | 8.11 | 44.92 | 38.88 | -149.96 | 100.6 | 89.11 | Upgrade
|
| Net Income Growth | -86.11% | 15.54% | - | - | 12.89% | -7.22% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| EPS (Basic) | 0.27 | 1.49 | 1.29 | -4.99 | 3.35 | 2.96 | Upgrade
|
| EPS (Diluted) | 0.27 | 1.49 | 1.29 | -4.99 | 3.35 | 2.96 | Upgrade
|
| EPS Growth | -86.11% | 15.54% | - | - | 12.89% | -7.22% | Upgrade
|
| Free Cash Flow | 0.65 | 99.2 | 109.46 | 21.29 | -57.08 | 124.8 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | 3.30 | 3.64 | 0.71 | -1.90 | 4.15 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | 3.600 | 2.206 | Upgrade
|
| Dividend Growth | - | - | - | -72.22% | 63.20% | - | Upgrade
|
| Gross Margin | 13.41% | 15.56% | 16.16% | 12.62% | 15.97% | 16.89% | Upgrade
|
| Operating Margin | 4.61% | 7.18% | 7.43% | 4.06% | 8.71% | 9.30% | Upgrade
|
| Profit Margin | 0.45% | 2.38% | 2.17% | -8.54% | 4.13% | 4.47% | Upgrade
|
| Free Cash Flow Margin | 0.04% | 5.27% | 6.10% | 1.21% | -2.34% | 6.26% | Upgrade
|
| EBITDA | 148.78 | 201.6 | 204.06 | 145.51 | 285.59 | 256.73 | Upgrade
|
| EBITDA Margin | 8.22% | 10.70% | 11.38% | 8.29% | 11.71% | 12.88% | Upgrade
|
| D&A For EBITDA | 65.31 | 66.25 | 70.75 | 74.27 | 73.24 | 71.27 | Upgrade
|
| EBIT | 83.47 | 135.35 | 133.3 | 71.24 | 212.34 | 185.46 | Upgrade
|
| EBIT Margin | 4.61% | 7.18% | 7.43% | 4.06% | 8.71% | 9.30% | Upgrade
|
| Effective Tax Rate | 89.52% | 65.21% | 70.34% | 332.63% | 51.57% | 52.14% | Upgrade
|
| Advertising Expenses | - | 9.54 | 8.98 | 9.1 | 12.47 | 6.04 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.